Sartorius Stedim Biotech (DIM) Q4 2024 earnings summary

Executive summary

• Achieved revised 2024 guidance for revenue and profitability, with market recovery gaining momentum and strong Q4 performance.

• Bioprocess Solutions sales were slightly above prior year, driven by consumables and advanced therapies, while equipment investments remained muted.

• Lab Products & Services sales were slightly below prior year due to soft end markets, especially in China, but profitability remained robust due to efficiency programs.

• Underlying growth drivers in bioprocessing and life sciences are becoming more relevant as temporary volatility fades.

• Efficiency program offset lower capacity utilization, maintaining robust profitability.

Financial highlights

• 2024 sales reached €3.4 billion, nearly flat year-over-year, with a 0.1% increase in constant currencies; order intake up 10.1%.

• Underlying EBITDA margin at 28.0% (€945 million), in line with guidance; underlying EPS (ordinary) was €4.05.

• Free cash flow doubled to €550 million, driven by working capital and CapEx management; operating cash flow increased 14.4% to €976 million.

• CapEx reduced to 12.1% of sales from 16.5% prior year.

• Equity ratio improved to 38.6% due to capital increase and strong cash flow; net debt reduced to €3.746 billion, leverage ratio at 4.0.

Outlook and guidance

• 2025 expected to see profitable, moderate growth above market, but below midterm average rates, mainly from recurring business.

• Underlying EBITDA margin expected to increase slightly on moderate revenue growth; focus remains on organic debt reduction and operational leverage.

• Quantitative guidance to be issued with Q1 results in April; midterm targets unchanged.